Get the Stockscreener App
106.24
3.00%
-3.29
After Hours:
106.26
0.02
+0.02%
Insmed Inc stock is traded at $106.24, with a volume of 2.43M.
It is down -3.00% in the last 24 hours and down -26.47% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$109.53
Open:
$108.47
24h Volume:
2.43M
Relative Volume:
0.85
Market Cap:
$23.03B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-18.50
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
-2.66%
1M Performance:
-26.47%
6M Performance:
-46.55%
1Y Performance:
+60.58%
1-Day Range:
$106.20
$110.83
1-Week Range:
$104.48
$110.95
52-Week Range:
$65.56
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
106.24 | 23.74B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insider Sell Alert: Michael Smith Sells 6,149 Shares of Insmed I - GuruFocus
Insmed chief legal officer Michael Smith sells $666,982 in shares - Investing.com
Insmed chief legal officer Michael Smith sells $666,982 in shares By Investing.com - Investing.com Canada
Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset - Quiver Quantitative
Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing - Moomoo
Insmed (INSM) legal chief sells 6,149 shares under Rule 10b5-1 plan - Stock Titan
Insmed CEO defends BRINSUPRI launch as sales surge, TPIP pipeline gains focus - MSN
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
TD Cowen Initiates Insmed(INSM.US) With Buy Rating, Announces Target Price $243 - Moomoo
Competitive Pressures Prompt Truist to Cut Target on Insmed (INSM) - Insider Monkey
INSM, FSLR, APTV: Dreaded death cross has formed on these stocks — what it means for investors - MSN
11 Best Long Term US Stocks to Buy Right Now - Insider Monkey
Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns - Yahoo Finance
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside - TipRanks
William Lewis lists proposed INSM share sales (05/2026) — INSM - Stock Titan
Insmed To Present at March 2026 Investor Conferences - GuruFocus
UBS Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $166 - Moomoo
Insmed, Inc. $INSM Shares Purchased by iA Global Asset Management Inc. - MarketBeat
Insmed Incorporated (INSM): Investor Outlook Reveals 84% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus - sharewise.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
AustralianSuper Pty Ltd Takes $1.74 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed CFO Sara Bonstein sells $961k in company stock - Investing.com UK
Insmed Inc files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Insmed Inc Files For Mixed Shelf Offering Size Not DisclosedSEC Filing - TradingView
Insmed (NASDAQ: INSM) files shelf registration to enable future stock and debt offers - Stock Titan
Darwin Global, affiliates hold 7.8% of INSMED (INSM) in 13G/A filing - Stock Titan
Insmed CFO Sara Bonstein sells $961k in company stock By Investing.com - Investing.com South Africa
Insmed Insiders Sold Shares Worth Over $3.2M - TradingView
Insmed (NASDAQ: INSM) director awarded 3,305 RSUs, now holds 246,081 shares - Stock Titan
Insmed (INSM) CFO sells 8,272 shares to cover RSU tax obligations - Stock Titan
Insmed (INSM) director Carol Schafer awarded 3,305 RSUs in equity grant - Stock Titan
INSMED (INSM) COO Roger Adsett sells 5,837 shares to cover RSU taxes - Stock Titan
Insmed (INSM) director granted 3,305 RSUs vesting after one year - Stock Titan
Insmed (NASDAQ: INSM) CMO sells 18,333 shares under Rule 10b5-1 plan - Stock Titan
Insmed (INSM) legal chief sells 4,109 shares to cover RSU taxes - Stock Titan
INSMED Inc (INSM) director Brennan receives 3,305 RSUs and reports 124,238 total shares - Stock Titan
Insmed (NASDAQ: INSM) director receives 3,305 RSUs equity award - Stock Titan
Director Leo Lee (NASDAQ: INSM) receives 3,305 RSUs equity grant - Stock Titan
INSMED (INSM) CEO Lewis sells 13,283 shares to cover RSU tax obligations - Stock Titan
Insmed (NASDAQ: INSM) investors approve board picks, pay and auditor - Stock Titan
NYLI Fiera SMID Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
INSM Maintained by Truist Securities -- Price Target Lowered to $185 - GuruFocus
[144] INSMED Inc SEC Filing - Stock Titan
Insmed stock (US4576693075): Truist cuts price target to $185 on competitive risks - AD HOC NEWS
Truist Financial Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Insmed | 4: Statement of changes in beneficial ownership of securities-Officer Flammer Martina M.D. - Moomoo
Truist cuts Insmed stock price target to $185 on competitive risks - Investing.com UK
Insmed chief medical officer Flammer sells $1.3 million in shares By Investing.com - Investing.com South Africa
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
2.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):